Last year, Mumbai-headquartered Sterlite Technologies Limited, set up its own manufacturing facility in Lugoff, South Carolina, to manufacture optical cables for the global market. The plant in the U.S.: is strategically located closer to the customers in the region for speedier delivery, increases manufacturing capacity to meet the growing demand...
India’s Sun Pharma Buys Concert Pharmaceuticals
Mumbai headquartered Sun Pharmaceutical Industries Limited, India's largest drugmaker, acquired Lexington, MA-based Concert Pharmaceuticals Inc., for $576 million in cash. Sun Pharma offered Concert $8 per share, representing a premium of 16% to the stock's last close. Concert's lead candidate, deuruxolitinib, is currently being evaluated in a late-stage study as...
Apple Launches Store in Mumbai
Apple’s much-awaited own branded retail store in India, will open to the public in April at the Jio World Drive Mall in Mumbai's upmarket Bandra Kurla Complex area. After this launch, Apple plans to open another retail store in Delhi-NCR some time between April and June. The designs on the...
Hindustan Unilever’s Market Cap Reaches 67% of Parent
In the first week of October 2022, the Market Capitalization of Mumbai- headquartered Hindustan Unilever (HUL) reached 67% of its parent company Unilever based in London, UK. HUL’s m-cap touched $77 billion as compared to Unilever’s $115 billion, a report in Economic Times said. Unilever’s market capitalization has deteriorated in...
Nihon Kohden to Build its Largest Manufacturing Facility in India
Model Economic Township or MET City, a wholly-owned subsidiary of Mumbai-based Reliance Industries said it was developing a world-class greenfield smart city near Gurugram, Haryana in the Delhi National Capital Region. In this industrial township, Tokyo-based manufacturer of medical devices Nihon Kohden Corporation will build its largest facility in India....
India’s Glenmark Develops Novel Oncology Therapy
Mumbai-based Glenmark Pharmaceuticals announced that its subsidiary Glenmark Specialty received approval from the Indian drug regulator, Drug Controller General of India (DCGI), to conduct a Phase 1 clinical trial of its novel small molecule, GRC 54276. It also plans to file an Investigational New Drug program in the U.S. along...